Protein Expression Systems Market By Expression System (Mammalian Expression Systems, Insect Expression Systems, Bacterial Expression Systems, Plant Expression Systems, Yeast Expression Systems, and Cell Free Expression Systems), By End-use Industry (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Other End Users), By Application (Therapeutic Applications, Industrial Application, and Research Applications), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2032

Protein Expression System Market accounted for US$ 3.8 billion in 2022 and is estimated to be US$ 11.30 billion by 2032 and is anticipated to register a CAGR of 11.6%. 

The Protein Expression System Market focuses on providing biotechnological methods and systems to generate and produce specialized proteins by manipulating gene expression in an organism so as to allow expression of a significant amount of a recombinant gene.

The constant increase in the number of chronic diseases and geriatric diseases due to the growing adoption of unhealthy lifestyles is another factor leading to the growth of the target market. The geriatric population is more prone to suffer from numerous diseases due to low immunity and aging related psychological changes. Thereby, the chance of developing various diseases, including diabetes and cancer, is rising as the geriatric population is rising, which in turn is boosting the growth.

For instance, in December 2022, according to an article published by the Indian Council of Medical Research, it was reported that cancer cases are speculated to increase from 14.6 lakh in the year 2022 to 15.7 lakh in the year 2025 in India.

Rising Demand for Protein Biologics

The increase in the usage of protein expression products and services, has been leading to a rising demand for Protein Biologics, which in turn is driving the growth of this market. Most of the chronic diseases like cancer, autoimmune diseases and other numerous serious diseases are treated using biologics. Vaccines, blood and blood components, and recombinant therapeutic proteins are examples of biologics, which are most used, eventually leading to the growth of the Protein Expression Systems Market.

For instance, in 2021, FDA (Food and drug Administration) approved almost 50 novel drugs. One-of-a-kind antibodies, pegylated proteins, hormones, and enzymes made up the other 14 of these biologics, all of which needed protein expression. Additionally, Evusheld (co-package of Tixagevimab with Cilgavimab) was approved as a prophylactic for the prevention of the infection.

Rising Occurrences of Target Illnesses

The rise in cases of diseases like cancer, cardiovascular disease, and genetic disorders are increasing, eventually leading to the growth of the target market. Insulin is one protein-based drug that has had incredible success in treating a variety of diseases, which in turn has been leading to the growth of the Protein Expression Systems Market.

For instance, in December 2022, according to CDC (Centers for Disease Control and Prevention), it was reported that in the United States, 1,603,844 new instances of cancer had occurred, and 602,347 cancer-related deaths were recorded. 403 new instances of cancer and 144 cancer-related deaths were recorded for every 100,000 persons.

Restrains of the Protein Expression Systems Market:

Undesired post-translational modifications and purifications is the major factor restraining the growth of the target market. The process of protein expression results in the production of crude proteins. These are removed and purified once more. Expression and purification of proteins are frequently difficult processes because of the inherent complexity of proteins in general.

For instance, target proteins frequently associate with the plasma membrane when trans-membrane domains or GPI-anchor sequences are present, which compromises protein production. The host cells experience unanticipated physiological changes as a result of the overexpression and accumulation of the target protein, which lead to the creation of misfolded proteins and protein destruction by the host proteases, eventually restraining the growth of the Protein Expression Systems Market.

Expression System Insight

On the basis of Expression System, Protein Expression Systems Market is segmented into Mammalian Expression Systems, Insect Expression Systems, Bacterial Expression Systems, Plant Expression Systems, Yeast Expression Systems, and Cell Free Expression Systems.

End-use Industry Insight

On the basis of End-use Industry, Protein Expression Systems Market is segmented into Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Other End Users.

Application Insight

On the basis of Application, Protein Expression Systems Market is segmented into Therapeutic Applications, Industrial Application, and Research Applications.

Regional Insights:

On the basis of Region, the Protein Expression Systems Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the target market in the near future, owing to the rising demand for protein biologics and rising prevalence for chronic diseases, their advancements in technology, incorporation of advanced devices, improved healthcare facilities as well as research and development programs. 

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Protein Expression Systems Market report based on Product, Application, Expression System, End-Users and Region:

Protein Expression Systems Market, By Expression System:

• Mammalian Expression Systems
• Insect Expression Systems
• Bacterial Expression Systems
• Plant Expression Systems
• Yeast Expression Systems
• Cell Free Expression Systems

Protein Expression Systems Market, By End-use Industry:

• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Other End Users

Protein Expression Systems Market, By Application:

• Therapeutic Applications
• Industrial Application
• Research Applications

Protein Expression Systems Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating the Protein Expression Systems Market includes, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., EMD Millipore, Life Technologies Corporation, Oxford Expression Technologies Ltd., Promega Corporation, QIAGEN N.V., TAKARA BIO INC. and Thermo Fisher Scientific Inc., New England Biolabs Inc., and others.

Recent Development:

• In September 2021, Aviva Systems Biology launched one of its new “Protein on Demand”, which is a semi-custom recombinant protein portfolio for life scientists carrying out basic research and preclinical studies.
• In June 2021, Qiagen launched its CRISPR products, “QIAprep&amp CRISPR Kit” and “CRISPR Q-Primer Solution”, to analyse edited genetic material with a higher speed and more efficiency.
• In June 2021, Thermo Fisher Scientific Inc. (US) along with Advanced Electrophoresis Solutions Ltd. (Canada) signed up an agreement to incorporate essential protein separation techniques with mass spectrometry to help advance therapeutic protein development through a well-organized characterization.
• In June 2020, Lonza Group AG (Switzerland) launched “GSv9”, which is a chemically defined media and feeds platform specifically developed to enhance the performance of the GS Gene Expression System for optimized recombinant protein production.

• Agilent Technologies, Inc.*
• Bio-Rad Laboratories, Inc.
• EMD Millipore
• Life Technologies Corporation
• Oxford Expression Technologies Ltd.
• Promega Corporation
• QIAGEN N.V.
• TAKARA BIO INC.
• Thermo Fisher Scientific Inc.
• New England Biolabs Inc.